Teva’s Fails to Invalidate Proctor & Gamble’s Patent for Actonel

Teva filed a new drug application to market a generic version of Actonel, the osteoporosis drug in the U.S., asserting that the Procter & Gamble patent wasn’t valid. However, the validity of the patent was upheld in a ruling by the U.S. District Court of Delaware which rejected Teva’s claims and gives Procter & Gamble Co. the exclusive right to market Actonel in the States.

Teva Pharmaceutical Industries Ltd. (TEVA) announced on Friday that it will appeal the decision.



Categories: drugs, Intellectual Property, Israel IP, Israel Related, News, Patents, pharmaceuticals, pharmaceuticals and Biotechnology

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: